Recent Updates
Recently added Catalysts
GENB Positive Sentiment

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Key Takeaway: Generate Biomedicines, Inc. announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference scheduled for June 8, 2026. The event will feature a live webcast available on the company's investor website, with an archived replay to follow. Generate Biomedicines focuses on advancing programmable biology to create optimized therapeutics.
Price reaction · baseline $13.08 (2026-05-27 close) · hit after-hours · clean, no other GENB news in the window
day 0 close
+0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prestigious healthcare conference
  • Opportunity to showcase innovative generative biology platform
  • Live webcast allows broader audience engagement

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~23 mo
Low dilution risk
Lead asset
GB-0895
Phase 3 · Severe Asthma

Full Press Release Details

SOMERVILLE, Mass.,May 28, 2026/PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ:GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026.
A live webcast is expected to be available in the Events and Presentations section of the Company's investor website atinvestors.generatebiomedicines.com. An archived replay is also expected to be available following the presentation.
About Generate:BiomedicinesGenerate (NASDAQ:GENB) is a clinical-stage generative biology company founded at the intersection of machine learning, biological engineering, and medicine, advancing a new era of programmable biology to engineer better medicines for patients, faster. The Generate Platform integrates computational design with large-scale biological experimentation, enabling the creation of novel, optimized therapeutics that address historically undruggable and hard-to-drug targets, as well as known targets in new and more effective ways. The platform has enabled the generation of a broad pipeline of therapies across multiple therapeutic areas and protein-based modalities, addressing health challenges out of reach of traditional approaches. Founded in 2018, Generate is leading a fundamental shift from drug discovery to drug generation. Learn more atwww.generatebiomedicines.com,or follow us on X, LinkedIn, and YouTube.

Generate Media ContactMegan McLaughlin[email protected]

Frequently Asked Questions

When is Generate Biomedicines participating in the conference?

Generate Biomedicines will participate in the conference on June 8, 2026.

Where can I watch the conference webcast?

The live webcast will be available on the company's investor website.

What is the focus of Generate Biomedicines?

Generate Biomedicines focuses on programmable biology to create optimized therapeutics.

Is there a replay available after the conference?

Yes, an archived replay will be available following the presentation.

Last updated: May 28, 2026